ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease

NEXT STORY
Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome
PREV STORY
Genesis Healthcare Reports Third Quarter 2020 Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

In-Vitro Diagnostics Market, 2023

Dublin, June 23, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition ...

author_avatar
NASDAQ Market News

Genocea Biosciences Reports Second Quarter 2017 Financial Results

- Recently reported positive top-line 12-month Phase 2b data for GEN-003 in genital herpes ...

author_avatar
NASDAQ Market News

Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress

ROCKVILLE, Md., March 24, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a ...

author_avatar
NASDAQ Market News